Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 204

1.

Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents.

Billinger M, Räber L, Hitz S, Stefanini GG, Pilgrim T, Stettler C, Zanchin T, Pulver C, Pfäffli N, Eberli F, Meier B, Kalesan B, Jüni P, Windecker S.

Am Heart J. 2012 May;163(5):876-886.e2. doi: 10.1016/j.ahj.2012.02.014.

PMID:
22607867
[PubMed - indexed for MEDLINE]
2.

Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.

King L, Byrne RA, Mehilli J, Schömig A, Kastrati A, Pache J.

Catheter Cardiovasc Interv. 2013 Jan 1;81(1):E23-8. doi: 10.1002/ccd.24375. Epub 2012 May 4.

PMID:
22431239
[PubMed - indexed for MEDLINE]
3.

2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.

Byrne RA, Kastrati A, Tiroch K, Schulz S, Pache J, Pinieck S, Massberg S, Seyfarth M, Laugwitz KL, Birkmeier KA, Schömig A, Mehilli J; ISAR-TEST-2 Investigators.

J Am Coll Cardiol. 2010 Jun 8;55(23):2536-43. doi: 10.1016/j.jacc.2010.03.020. Epub 2010 Apr 22. Erratum in: J Am Coll Cardiol. 2010 Jul 13;56(3):243.

PMID:
20417052
[PubMed - indexed for MEDLINE]
Free Article
4.

A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).

Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B, Seidelberger B, Iñiguez A, Gómez-Recio M, Masotti M, Velázquez MT, Sanchís J, García-Touchard A, Zueco J, Bethencourt A, Melgares R, Cequier A, Dominguez A, Mainar V, López-Mínguez JR, Moreu J, Martí V, Moreno R, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C; RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology.

J Am Coll Cardiol. 2014 Apr 15;63(14):1378-86. doi: 10.1016/j.jacc.2013.12.006. Epub 2014 Jan 8.

PMID:
24412457
[PubMed - indexed for MEDLINE]
5.

Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents.

Stefanini GG, Kalesan B, Pilgrim T, Räber L, Onuma Y, Silber S, Serruys PW, Meier B, Jüni P, Windecker S.

JACC Cardiovasc Interv. 2012 Mar;5(3):301-10. doi: 10.1016/j.jcin.2011.11.011.

PMID:
22440496
[PubMed - indexed for MEDLINE]
Free Article
6.

Impact of diabetes mellitus on patients with unprotected left main coronary artery lesion disease treated with either percutaneous coronary intervention or coronary-artery bypass grafting.

Luo Y, Yu X, Chen F, Du X, He J, Gao Y, Zhang X, Zhang Y, Ren X, Lv S, Ma C.

Coron Artery Dis. 2012 Aug;23(5):322-9. doi: 10.1097/MCA.0b013e3283564961.

PMID:
22750912
[PubMed - indexed for MEDLINE]
7.

Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.

Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari DE; ENDEAVOR IV Investigators.

JACC Cardiovasc Interv. 2010 Oct;3(10):1043-50. doi: 10.1016/j.jcin.2010.07.008.

PMID:
20965463
[PubMed - indexed for MEDLINE]
Free Article
8.

A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.

Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ.

JACC Cardiovasc Interv. 2011 Mar;4(3):310-6. doi: 10.1016/j.jcin.2010.12.006.

PMID:
21435609
[PubMed - indexed for MEDLINE]
Free Article
9.

The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions.

Uchida T, Popma J, Stone GW, Ellis SG, Turco MA, Ormiston JA, Muramatsu T, Nakamura M, Nanto S, Yokoi H, Baim DS.

JACC Cardiovasc Interv. 2010 Apr;3(4):403-11. doi: 10.1016/j.jcin.2010.01.010.

PMID:
20398868
[PubMed - indexed for MEDLINE]
Free Article
10.

Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program.

Farooq V, Vranckx P, Mauri L, Cutlip DE, Belardi J, Silber S, Widimsky P, Leon M, Windecker S, Meredith I, Negoita M, van Leeuwen F, Neumann FJ, Yeung AC, Garcia-Garcia HM, Serruys PW.

Heart. 2013 May;99(9):626-33. doi: 10.1136/heartjnl-2012-303368. Epub 2013 Mar 6.

PMID:
23468513
[PubMed - indexed for MEDLINE]
11.

Paclitaxel versus sirolimus eluting stents in diabetic patients: does stent type and/or stent diameter matter?: long-term clinical outcome of 2,429-patient multicenter registry.

Tarantini G, Facchin M, Capodanno D, Musumeci G, Saia F, Menozzi A, Meliga E, Mancone M, Lettieri C, Tamburino C.

Catheter Cardiovasc Interv. 2013 Jan 1;81(1):80-9. doi: 10.1002/ccd.24445. Epub 2012 Nov 8.

PMID:
22511311
[PubMed - indexed for MEDLINE]
12.

Five-year results of the Multicenter Randomized Controlled Open-Label Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients with De Novo Native Coronary Artery Lesions (SCORPIUS) study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients.

Sinning JM, Baumgart D, Werner N, Klauss V, Baer FM, Hartmann F, Drexler H, Motz W, Klues H, Voelker W, Pfannebecker T, Stoll HP, Nickenig G; SCORPIUS Study.

Am Heart J. 2012 Mar;163(3):446-53, 453.e1. doi: 10.1016/j.ahj.2011.12.010.

PMID:
22424016
[PubMed - indexed for MEDLINE]
13.

Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.

Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, Lima AA, Caramori PR, Medeiros CR, Barbosa MR, Brito FS Jr, Ribeiro EE, Martinez EE; PAINT trial investigators.

Catheter Cardiovasc Interv. 2009 Nov 1;74(5):665-73. doi: 10.1002/ccd.22166.

PMID:
19670303
[PubMed - indexed for MEDLINE]
14.

Long-term outcomes of sirolimus-eluting stents vs. paclitaxel-eluting stents in unprotected left main coronary artery bifurcation lesions.

Song PS, Ryu DR, Song YB, Hahn JY, Choi JH, Choi SH, Lee SH, Hong KP, Park JE, Gwon HC.

Clin Cardiol. 2011 Jun;34(6):378-83. doi: 10.1002/clc.20887. Epub 2011 Apr 27.

PMID:
21538383
[PubMed - indexed for MEDLINE]
15.

Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial.

Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G.

Am Heart J. 2009 Oct;158(4):e43-50. doi: 10.1016/j.ahj.2009.03.016.

PMID:
19781402
[PubMed - indexed for MEDLINE]
16.

Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.

Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schömig A, Kastrati A; ISAR-DESIRE 2 Investigators.

J Am Coll Cardiol. 2010 Jun 15;55(24):2710-6. doi: 10.1016/j.jacc.2010.02.009. Epub 2010 Mar 11.

PMID:
20226618
[PubMed - indexed for MEDLINE]
Free Article
17.

Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus.

Ali RM, Degenhardt R, Zambahari R, Tresukosol D, Ahmad WA, Kamar Hb, Kui-Hian S, Ong TK, bin Ismail O, bin Elis S, Udychalerm W, Ackermann H, Boxberger M, Unverdorben M.

EuroIntervention. 2011 May;7 Suppl K:K83-92. doi: 10.4244/EIJV7SKA15.

PMID:
22027736
[PubMed - indexed for MEDLINE]
18.

Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.

Kirtane AJ, Patel R, O'Shaughnessy C, Overlie P, McLaurin B, Solomon S, Mauri L, Fitzgerald P, Popma JJ, Kandzari DE, Leon MB.

JACC Cardiovasc Interv. 2009 Oct;2(10):967-76. doi: 10.1016/j.jcin.2009.08.008.

PMID:
19850257
[PubMed - indexed for MEDLINE]
Free Article
19.

Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.

Wiemer M, Serruys PW, Miquel-Hebert K, Neumann FJ, Piek JJ, Grube E, Haase J, Thuesen L, Hamm C.

Catheter Cardiovasc Interv. 2010 Jun 1;75(7):997-1003. doi: 10.1002/ccd.22428.

PMID:
20517959
[PubMed - indexed for MEDLINE]
20.

Drug eluting stenting in bifurcation coronary lesions long-term results applying a systematic treatment strategy.

Assali AR, Vaknin-Assa H, Lev E, Teplitsky I, Dvir D, Brosh D, Bental T, Battler A, Kornowski R.

Catheter Cardiovasc Interv. 2012 Mar 1;79(4):615-22. doi: 10.1002/ccd.23180. Epub 2011 Dec 7.

PMID:
22162218
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk